Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490122 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL27906387 | 0.67 | — | — | |
| SCHEMBL22764070 | 0.65 | ADRA1A (0.35) | HRH3HRH4ALDH1A1FKBP5KMT2A | |
| SCHEMBL27494523 | 0.64 | — | — | |
| SCHEMBL19935942 | 0.64 | JAK2 (0.33) | NUDT1 | |
| SCHEMBL502104 | 0.64 | PKM (0.52) | HRH3HRH4ALDH1A1MEN1MAPT | |
| SCHEMBL26800848 | 0.64 | — | — | |
| SCHEMBL23943143 | 0.63 | NUDT1 (0.35) | NUDT1 | |
| SCHEMBL26812529 | 0.63 | HRH4 (0.42) | HRH3HRH4ALDH1A1FKBP5MEN1 | |
| SCHEMBL17700061 | 0.62 | CDK2 (0.43) | HRH3HRH4NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | HRH3 1226/4885HRH4 747/4885ALDH1A1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.